货号 | MAB2520-SP |
别名 | BNF-1; chordin-like 2; chordin-like protein 2; CHRDL2 |
反应种属 | Mouse |
应用 | Western Blot(1 µg/mL) Immunohistochemistry(8-25 µg/mL) Immunoprecipitation(25 µg/mL) |
目标/特异性 | Detects mouse Chordin-like 2/CHRDL2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human CHRDL2, recombinant mouse (rm) CHRDL1, or rmChordin is observed. |
使用方法 | Western Blot: 1 µg/mL Immunohistochemistry: 8-25 µg/mL Immunoprecipitation: 25 µg/mL |
来源 | Reconstitute at 0.5 mg/mL in sterile PBS. |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 25884 (Human); 69121 (Mouse) |
纯化方式 | Protein A or G purified from hybridoma culture supernatant |
免疫原 | Mouse myeloma cell line NS0-derived recombinant mouse Chordin-like 2/CHRDL2 Gln24-Leu426 Accession # Q8VEA6.1 |
生物活性 | Mouse |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
背景 | Chordin-like 2 (CHL2, CHRDL2, or BNF-1), is a secreted glycoprotein that functions as a BMP antagonist. It is expressed in chondrocytes in developing joint cartilage, osteoblasts, myotubes, brain, some carcinomas, and the genitourinary system (e.g. uterus, prostate, testis, bladder). CHL2 binds to multiple TGF-beta superfamily proteins including BMP-2, -4, -5, -6, -7, GDF-5, Activin A, and TSG. It prevents the binding of BMPs to type 1 and type 2 receptors as well as BMP-induced cellular responses. CHL2 reduces the rate of matrix deposition by mesenchymal cells, acting as a negative regulator of cartilage formation. |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Chordin-like 2/CHRDL2 in Embryonic Mouse Cartilage.Chordin-like 2/ CHRDL2 was detected in immersion fixed frozen sections of embryonic mouse cartilage (15 d.p.c.) using 25 µg/mL Rat Anti-Mouse Chordin-like 2/CHRDL2 Monoclonal Antibody (Catalog # MAB2520) overnight at 4 °C. Tissue was stained with the Anti-Rat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS017) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections. |